Special Considerations
- Minimization of medications with deleterious effects in HF should be emphasized.
- Negative inotropes (e.g., verapamil, diltiazem) should be avoided in patients with impaired ventricular contractility, as should over-the-counter β stimulants (e.g., compounds containing ephedra, pseudoephedrine hydrochloride).
- NSAIDs, which antagonize the effect of ACE inhibitors and diuretic therapy, should be avoided if possible.
- Administration of supplemental oxygen may relieve dyspnea, improve oxygen delivery, reduce the work of breathing, and limit pulmonary vasoconstriction in patients with hypoxemia but is not routinely recommended in patients without measurable hypoxemia.
- Sleep apnea has a prevalence rate as high as 50% in the HF population. Treatment of obstructive sleep apnea with nocturnal positive airway pressure improves symptoms and EF.1 However, treatment of central sleep apnea with adaptive servo-ventilation in patients with HFrEF was associated with increased mortality.2
- Dialysis or ultrafiltration may be beneficial in patients with severe HF and renal dysfunction who cannot respond adequately to fluid and sodium restriction and diuretics.3 Ultrafiltration is not superior to a scaled diuretic regimen in patients with acute HF and cardiorenal syndrome and is associated with higher rate of adverse events.4 Other mechanical methods of fluid removal such as therapeutic thoracentesis and paracentesis may provide temporary symptomatic relief of dyspnea. Care must be taken to avoid rapid fluid removal and hypotension.
- End-of-life considerations should be strongly considered in patients with advanced HF who are refractory to therapy. Discussions regarding the disease course, treatment options, survival, functional status, and advance directives should be addressed early in the treatment of the patient with HF. For those with end-stage disease (stage D, NYHA class IV) with multiple hospitalizations and severe decline in their functional status and quality of life, hospice and palliative care is recommended.5
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Bhat, Pavat, et al., editors. "Special Considerations." Washington Manual of Medical Therapeutics, 35th ed., Wolters Kluwer Health, 2016. The Washington Manual, www.unboundmedicine.com/washingtonmanual/view/Washington-Manual-of-Medical-Therapeutics/602711/all/Special_Considerations.
Special Considerations. In: Bhat PP, Dretler AA, Gdowski MM, et al, eds. Washington Manual of Medical Therapeutics. Wolters Kluwer Health; 2016. https://www.unboundmedicine.com/washingtonmanual/view/Washington-Manual-of-Medical-Therapeutics/602711/all/Special_Considerations. Accessed June 7, 2023.
Special Considerations. (2016). In Bhat, P., Dretler, A., Gdowski, M., Ramgopal, R., & Williams, D. (Eds.), Washington Manual of Medical Therapeutics (35th ed.). Wolters Kluwer Health. https://www.unboundmedicine.com/washingtonmanual/view/Washington-Manual-of-Medical-Therapeutics/602711/all/Special_Considerations
Special Considerations [Internet]. In: Bhat PP, Dretler AA, Gdowski MM, Ramgopal RR, Williams DD, editors. Washington Manual of Medical Therapeutics. Wolters Kluwer Health; 2016. [cited 2023 June 07]. Available from: https://www.unboundmedicine.com/washingtonmanual/view/Washington-Manual-of-Medical-Therapeutics/602711/all/Special_Considerations.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Special Considerations
ID - 602711
ED - Williams,Dominique,
ED - Bhat,Pavat,
ED - Dretler,Alexandra,
ED - Gdowski,Mark,
ED - Ramgopal,Rajeev,
BT - Washington Manual of Medical Therapeutics
UR - https://www.unboundmedicine.com/washingtonmanual/view/Washington-Manual-of-Medical-Therapeutics/602711/all/Special_Considerations
PB - Wolters Kluwer Health
ET - 35
DB - The Washington Manual
DP - Unbound Medicine
ER -